Limited Competition: Strategic Timing of Antiretroviral Treatment (START) (UM1)
The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support to complete the Strategic Timing of Antiretroviral Treatment (START) trial. START is a randomized clinical trial to determine if immediate initiation of antiretroviral treatment (ART) in HIV-positive patients is superior in delaying the occurrence of AIDS, non-AIDS events and death.
General information about this opportunity
Last Known Status
Deleted 12/20/2014 (Archived.)
Program Number
PAR-14-329 Federal Agency/Office
Agency: Department of Health and Human ServicesOffice: National Institutes of Health
Type(s) of Assistance Offered
Cooperative Agreement Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Other Eligible Applicants include the following: Only the current START awardee is eligible to apply to this limited competition FOA. What is the process for applying and being award this assistance?
Deadlines
11/19/2014 Other Assistance Considerations
Formula and Matching Requirements
This program does not have cost sharing or matching requirements. Who do I contact about this opportunity?
Headquarters Office
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
Website Address
http://grants.nih.gov/grants/guide/pa-files/PAR-14-329.html
E-mail Address
FBOWebmaster@OD.NIH.GOV
Financial Information
Obligations
$0.00
